<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1739">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138523</url>
  </required_header>
  <id_info>
    <org_study_id>DASO2018/PRO-00</org_study_id>
    <nct_id>NCT05138523</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)</brief_title>
  <official_title>Observational, Open Label Study With Direct Individual Benefit Assessing the Efficacy and Safety of Sofosdac® 400mg/60mg Tablets (400 mg Sofosbuvir and 60 mg of Daclatasvir) Treatment in Patients With Chronic Hepatitis C (HCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beker Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Unit, Jordan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beker Laboratories</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentric, observational, open-design study conducted to evaluate the efficacy and&#xD;
      safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C&#xD;
      (HCV)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BEKER laboratories developed the generic drug Sofosdac® 400 mg/60 mg Tablets as fixed dose&#xD;
      combination that contains two direct antiviral agents (400 mg Sofosbuvir and 60 mg&#xD;
      Daclatasvir) known to be pangenotypic in order to fulfill WHO plan to eradicate HCV by 2030.&#xD;
      BEKER conducted an observational clinical trial to evaluate the efficacy and safety of FDC&#xD;
      Sofosdac® 400 mg/60 mg treatment in Algerian patients with chronic hepatitis C (HCV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Actual">June 22, 2021</completion_date>
  <primary_completion_date type="Actual">November 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of RNA HCV 12 weeks after treatment cessation by acceptable quantification assay</measure>
    <time_frame>12 weeks after treatment cessation</time_frame>
    <description>A quantification assay is performed to all patients to detect RNA HCV in order to determine the proportion of patients who achieve SVR12 (Sustained Viral Response) defined as:&#xD;
RNA HCV &lt; LLOQ (Lower Limit of Quantification) 12 weeks after treatment cessation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of reported adverse events</measure>
    <time_frame>During treatment duration defined as: 24 weeks for cirrhotics, and 12 weeks for non-cirrhotic patients</time_frame>
    <description>Assessment of observed adverse events / adverse effects and serious adverse events related or not related to Sofosdac® treatment.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">99</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <arm_group>
    <arm_group_label>Non-cirrhotic</arm_group_label>
    <description>Non-cirrhotic HCV patients; 12 weeks treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhotic</arm_group_label>
    <description>Cirrhotic HCV patients; 24 weeks treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Sofosdac®</intervention_name>
    <description>Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir</description>
    <arm_group_label>Cirrhotic</arm_group_label>
    <arm_group_label>Non-cirrhotic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects in the study were enrolled from five centers (primary care facilities) across&#xD;
        different regions in the country; East, Center and West of Algeria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women age of 18 years old and older.&#xD;
&#xD;
          -  HCV chronic Infection, genotype 1 or 2 or 3 or 4 or 5 or 6&#xD;
&#xD;
          -  Naive&#xD;
&#xD;
          -  Bi-therapy failure, Tri-therapy 1st generation Telaprévir and Boceprevir, Sofosbuvir -&#xD;
             pegIFN - RBV failure&#xD;
&#xD;
          -  Evaluation of fibrosis by non-invasive methods (Fibroscan, Fib 4, APRI) performed&#xD;
             during the pre-inclusion period (of at least one month) or A Liver biopsy puncture of&#xD;
             at least 24 months before the inclusion visit.&#xD;
&#xD;
          -  Fibrosis according to Metavir score: F0, F1, F2, F3, F4.&#xD;
&#xD;
          -  Compensated Cirrhosis Child-Pugh A or&#xD;
&#xD;
          -  Decompensated Cirrhosis (This point is applicable for patients who have cirrhosis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under amiodarone&#xD;
&#xD;
          -  Hepatocellular carcinoma HCC&#xD;
&#xD;
          -  Haemodialysis&#xD;
&#xD;
          -  Creatinine Clearance &lt; 30ml/min&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Impossibility of using effective masculine or feminine contraception during the study&#xD;
             and 6 months after treatment cessation.&#xD;
&#xD;
          -  Medications triggering conduction disturbances with long QT, 30 days prior to&#xD;
             inclusion&#xD;
&#xD;
          -  QT prolongation &gt; 450 ms&#xD;
&#xD;
          -  Personal or familial history of torsade de pointes&#xD;
&#xD;
          -  Allergies to nucleosi(ti)des analogues.&#xD;
&#xD;
          -  Advanced cardiopulmonary pathology&#xD;
&#xD;
          -  Malignant neoplasia&#xD;
&#xD;
          -  The intake of anticonvulsants: Carbamazepine, eslicarbazepine, fosphenytoin,&#xD;
             phenytoin, oxcarbazepine, pentobarbital, phenobarbital, primidone or the&#xD;
             antimycobacterial agents: Rifabutin, rifampin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil Debzi, MD; Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Mustapha Hepatology department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boufarik Public Hospital</name>
      <address>
        <city>Boufarik</city>
        <state>Blida</state>
        <zip>9001</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mustapha Pacha Teaching Hospital</name>
      <address>
        <city>Algiers</city>
        <zip>16000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khenchla Public Hospital</name>
      <address>
        <city>Khenchla</city>
        <zip>40000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oran Teaching Hospital</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Cirrhotic</keyword>
  <keyword>non-cirrhotic</keyword>
  <keyword>sofosdac</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>daclatasvir</keyword>
  <keyword>fixed-dose combination</keyword>
  <keyword>FDC</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>pangenotypic</keyword>
  <keyword>genotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD collected will be available to other researchers upon their request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

